Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03889340 · ClinicalTrials.gov registry record
Study of Brain Cools Device in Patients Resuscitated From Cardiac Arrest
A clinical trial of Cardiac Arrest With Successful Resuscitation, sponsored by Adam Frisch.
- Completed
- Registry status
- 38
- Enrollment target
- 1
- Study location
NCT03889340: Completed study of Cardiac Arrest With Successful Resuscitation, sponsored by Adam Frisch.
NCT03889340 is a study of Cardiac Arrest With Successful Resuscitation that has completed, run by Adam Frisch. The registered enrollment target is 38 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03889340, a study of Cardiac Arrest With Successful Resuscitation, has completed, sponsored by Adam Frisch.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This submission is a pilot in which the new IQool Warming System device will be used to maintain the temperature of adult patients in cardiac arrest within a range of within a range of 32°C to 38.5°C (89.6°F to 101.3°F). The IQool Warming System has received a 510 K Clearance by the FDA.
Primary Outcome
Induction of hypothermia will occur at a rate of at least 1C/hr
Conditions Studied
Interventions
- DEVICE IQool
Study Locations (1)
Pennsylvania
- UPMC Presbyterian Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-12-01 |
What the finished NCT03889340 record still lists
NCT03889340 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 1 condition, with Cardiac Arrest With Successful Resuscitation appearing as the primary indexed condition, and to 1 intervention - of which IQool is the first listed.
NCT03889340 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03889340 about?
NCT03889340 is a clinical study titled "Study of Brain Cools Device in Patients Resuscitated From Cardiac Arrest". This submission is a pilot in which the new IQool Warming System device will be used to maintain the temperature of adult patients in cardiac arrest within a range of within a range of 32°C to 38.5°C (89.6°F to 101.3°F). The IQool Warming System has received a 510 K Clearance by the FDA.
What is the current status of trial NCT03889340?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2019-05-01. Estimated completion is 2021-12-01.
What conditions does trial NCT03889340 study?
This clinical trial studies the following conditions: Cardiac Arrest With Successful Resuscitation.
What interventions are being tested in trial NCT03889340?
The interventions under investigation include: IQool (DEVICE).
Who is sponsoring clinical trial NCT03889340?
This trial is sponsored by Adam Frisch, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03889340 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Arrest With Successful Resuscitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI